Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Condensed Consolidated Statements of Operations
Net Revenues	$ 49,774	$ 52,887
Operating Expenses:
Cost of sales (excluding depreciation and amortization)	21,804	14,725
Research and development	6,344	4,373
Selling, general, and administrative	13,683	13,284
Depreciation and amortization	11,183	16,103
Cortrophin pre-launch charges	4,602	0
Total Operating Expenses	57,616	48,485
Operating (Loss)/Income	(7,842)	4,402
Other Expense, net
Interest expense, net	(2,032)	(3,354)
Other income /(expense), net	10	(130)
(Loss)/Income Before Benefit/(Provision) for Income Taxes	(9,864)	918
Benefit/(provision) for income taxes	2,853	(469)
Net (Loss)/Income	$ (7,011)	$ 449
Basic and Diluted (Loss)/Earnings Per Share:
Basic (Loss)/Earnings Per Share	$ (0.59)	$ 0.04
Diluted (Loss)/Earnings Per Share	$ (0.59)	$ 0.04
Basic Weighted-Average Shares Outstanding	11,902	11,747
Diluted Weighted-Average Shares Outstanding	11,902	11,823